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Post-ischemic inﬂammation is an essential step in the progression of brain
ischemia-reperfusion injury. In this review, we focus on the post-ischemic inﬂammation
triggered by inﬁltrating immune cells, macrophages, andT lymphocytes. Brain ischemia is
a sterile organ, but injury-induced inﬂammation is mostly dependent on Toll-like receptor
(TLR) 2 andTLR4. Some endogenousTLR ligands, high mobility group box 1 (HMGB1) and
peroxiredoxin family proteins, in particular, are implicated in the activation and inﬂamma-
tory cytokine expression in inﬁltrating macrophages. Following macrophage activation, T
lymphocytes inﬁltrate the ischemic brain and regulate the delayed phase inﬂammation. IL-
17-producing γδT lymphocytes induced by IL-23 from macrophages promote ischemic brain
injury, whereas regulatory T lymphocytes suppress the function of inﬂammatory media-
tors. A deeper understanding of the inﬂammatory mechanisms of inﬁltrating immune cells
may lead to the development of novel neuroprotective therapies.
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INTRODUCTION
Stroke is a leading cause of death and disability worldwide. The
most common type of stroke is ischemic stroke (e.g., approxi-
mately 70% of strokes in Japan are ischemic). However, intra-
venous administration of tissue plasminogen activator (tPA) is
the only globally approved treatment for ischemic stroke, and it
is a time-dependent therapy that must be provided within 4.5 h
after stroke onset. Thus, there is a need for an efﬁcacious therapy
that can be administered beyond this timewindow,one that targets
neuroprotection rather than clot dissolution (Lo, 2010;Moskowitz
et al., 2010).
Brain infarction is tissue death caused by ischemia due to
severe stenosis or occlusion of a cerebral artery. Ischemic brain
tissue is deprived of oxygen, glucose, and lipids, and eventually
becomes necrotic. Brain inﬂammation occurs in this necrotic
brain tissue, following the breakdown of the blood-brain barrier
(BBB) and inﬁltration of blood immune cells. Inﬁltrating immune
cells promote ischemic brain inﬂammation by producing vari-
ous inﬂammatory mediators, and also clear away necrotic debris.
After the demolition of necrotic debris has been completed, brain
inﬂammation subsides.
Despite intensive studies, the complexity of the brain inﬂam-
mation mechanism has thus far prevented sufﬁcient clariﬁcation
(Eltzschig and Eckle, 2011; Iadecola and Anrather, 2011; Macrez
et al., 2011). Macrophages and neutrophils are pivotal players in
the various processes of brain inﬂammation,but themechanismof
their activation is still unknown. In addition, T or B lymphocytes
have been also reported to participate in delayed brain inﬂam-
mation. This review focuses on the mechanism of ischemic brain
inﬂammation triggered and sustained by inﬁltrating immune cells.
POST-ISCHEMIC INFLAMMATION IN THE EARLY PHASE OF
BRAIN ISCHEMIA
Severe ischemia induces hypoxia and glucose deprivation in brain
tissue. Calcium and sodium ions are stored within brain cells and
glutamate is released into the extracellular compartment. The pro-
duction of reactive oxygen species (ROS) activates platelets and
endothelial cells, leading to microvascular occlusion. Oxidative
stress reduces the beneﬁcial effects of nitric oxide (NO), a potent
vasodilator and inhibitor of platelet aggregation and leukocyte
adhesion, in endothelial cells. Oxidative stress and the inﬂam-
matory cascade alter the permeability of the BBB. The activation
of matrix metalloproteinases (MMPs) and the expression of var-
ious other proteases lead to BBB breakdown which exacerbates
leukocyte extravasation. Intravascular leukocytes ﬁrmly adhere to
activated endothelium by the interaction of endothelial expres-
sion of intercellular adhesion molecule-1 (ICAM-1) and leukocyte
β2 integrins (Iadecola and Anrather, 2011). The inﬁltration of
leukocytes is enhanced by BBB breakdown and by chemokines.
Brain cells, including astrocytes, oligodendrocytes, endothe-
lium, and pericytes, constitute a neurovascular network, which
is essential for metabolic requirement of neurons (Iadecola, 2004;
Fraser, 2011). These brain cells also contribute to triggering post-
ischemic inﬂammation by producing inﬂammatory mediators.
TNF-α, IL-1β, NOS (nitric oxide synthetase), and MMPs which
enhance cerebrovascular permeability and exaggerate brain edema
(Takano et al., 2009; Morancho et al., 2010). Thus, Inﬁltrat-
ing leukocytes and injured brain cells produce various inﬂam-
matory mediators, leading to the beginning of post-ischemic
inﬂammation (Barone and Feuerstein, 1999; Figure 1).
INNATE INFLAMMATORY CYTOKINES AND INFLAMMATORY
MEDIATORS
Various cytokines and mediators are produced from inﬁltrating
immune cells and brain cells as a result of ischemic changes of
brain. IL-1β is expressed in ischemic brain tissue within 30min
after stroke onset. IL-1β directly induces apoptosis of neuronal
cells and enhances the expression of chemokine (RANTES, etc.)
in microglia and astrocytes. IL-1β is considered to be a neurotoxic
mediator, given that the loss of IL-1β function is reported to reduce
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FIGURE 1 | Post-ischemic inflammation in the brain.Within 24 h after
ischemic stroke onset, various inﬂammatory mediators are expressed in
ischemic brain tissue. ICAM-1 promotes leukocytes inﬁltration. Cytokines
activate inﬁltrating leukocytes and directly induce ischemic injury in brain
cells. Matrix metalloproteinases (MMPs) alter the permeability of epithelial
cells and are implicated in BBB breakdown. EndogenousTLR ligands
(DAMPs) are released from necrotic brain cells and activate inﬁltrating
immune cells. These inﬂammatory mediators trigger post-ischemic
inﬂammation by inﬁltrating leukocytes. There are currently few effective
therapies for this phase of leukocyte inﬁltration.
infarct size (Boutin et al., 2001). IL-1β is produced in an inactivate
form, pro-IL-1β, which is cleaved by caspase-1 to become an active
17 kDa form. Recently, the mechanism of IL-1β production and
caspase-1 activation mediated by inﬂammasome has been the sub-
ject of particular attention. Inﬂammasome has been shown to be
present in neurons, astrocytes, microglia, and macrophages in the
ischemic brain (Abulaﬁa et al., 2009; Chakraborty et al., 2010).
Several types of inﬂammasome have been discovered, denoted
NALP1, NALP3, AIM, and so on, but the particular type most
important in ischemic brain injury remains unknown. Hypoxia
or ATP is reported to activate inﬂammasome,which then activates
caspase-1 and induces IL-1β production (Martinon et al., 2002).
In addition, IL-1β is mostly produced from monocytes which are
activated by endogenous Toll-like receptor (TLR) ligands, given
that IL-1β mRNA level in inﬁltrating mononuclear cells is drasti-
cally reduced inTLR2/4-double deﬁcientmice after ischemic brain
injury.
TNF-α is another importantmediator implicated in the pathol-
ogy of the ischemic brain. TNF-α is expressed in ischemic brain
tissue within 1 h after stroke onset, and upregulation of the TNF
receptors is observed thereafter. TNF-α exercises neurotoxic effects
by inducing apoptotic neuronal cell death and enhancing MHC
class II and ICAM-1 expression in astrocytes, leading to leukocyte
inﬁltration andBBBbreakdown. TNF-α gene knockout (KO)mice
or anti-TNF-α neutralizing antibody administration has been
shown to reduce infarct volume, compared with that in control
mice. However, TNFR KO mice, which lack both p75 and p50
genes, exhibit enlargement of infarct volume on day 1 following
ischemic brain injury, indicating that TNF-α can be considered
to function as both a neurotoxic and a neuroprotective mediator
(Hallenbeck, 2002). It appears that the opposing functions, toxic
or protective, depends on the type of brain cell involved. TNF-α
promotes post-ischemic inﬂammation but also participates in a
negative feedback loop to suppress inﬂammatory signal cascades,
and it controls the duration of post-ischemic inﬂammation by
regulating these two functions.
IL-6 is also expressed in ischemic brain tissue, but ischemic
brain damage is not attenuated in IL-6 KO mice or in anti-IL-
6R antagonistic antibody-treated mice (Yamashita et al., 2005).
However, it has been recently reported that IL-6 produced from
brain cells contributes to neoangiogenesis and neuronal sur-
vival through STAT3 activation (Jung et al., 2011; Gertz et al.,
2012). Consistent with this, the inhibition of JAK/STAT path-
way or the enhanced role of SOCS3 (negative regulator of
JAK/STAT pathway) has been reported to promote neuronal
cell death (Yadav et al., 2005; Yamashita et al., 2005). Thus, it
is possible that IL-6 protects neuron from cell death, although
a signiﬁcant role of IL-6 in brain ischemia has not yet been
established.
Matrix metalloproteinases are essential neurotoxic mediators
that promote BBB breakdown and post-ischemic inﬂammation.
Functionally similar to IL-1β, MMPs induce apoptotic neuronal
cell death by TNF-α and FasL processing. The neurotoxic func-
tion of MMP-9 is particularly established, given that infarct size
is reduced in MMP-9-deﬁcient mice compared to that in con-
trol mice (Asahi et al., 2000). Intercellular adhesion molecule-1
(ICAM-1) is another neurotoxic mediator. The increased expres-
sion of ICAM-1 observed in cerebrovascular endothelial cells is
implicated in the promotion of leukocyte inﬁltration. ICAM-
1-deﬁcient mice reveal attenuated ischemic damage and the
administration of anti-ICAM-1 antibody decreases the number
of inﬁltrating immune cells (Connolly et al., 1996; Liesz et al.,
2011).
Chemokines are also important enhancers of post-ischemic
inﬂammation. Chemokines (RANTES, MCP-1, IL-8, etc.) have
been reported to promote leukocyte inﬁltration into the ischemic
brain (Terao et al., 2008, 2009; Strecker et al., 2011). Although
the chemokines for lymphocyte inﬁltration remain unknown,
CCL12,CCL20,and their receptor,CCR6,are essential for the exac-
erbation of experimental autoimmune encephalomyelitis (EAE;
Martin et al., 2009; Reboldi et al., 2009). Whether these lympho-
cyte chemokines also function in acute organ injury, such as brain
ischemia, should be elucidated in the future.
Sphingosine-1-phosphate (S1P) is a bioactive phospholipid.
At sites of tissue injury, S1P is mainly released from platelets
and mediates its effect via activation of cell-surface S1P recep-
tors, which are ubiquitously expressed in brain cells (Dev et al.,
2008). S1P receptors are also present on the surface of T lym-
phocytes; therefore, S1P has been thought to play an essential
role in T lymphocyte inﬁltration of inﬂammatory tissue. Recently,
the therapeutic effect of FTY720 (ﬁngolimod), a functional S1P
receptor antagonist, has attracted attention. The administration of
FTY720 has been shown to attenuate ischemic brain damage and
decrease the number of inﬁltrating T lymphocytes in the ischemic
brain (Shichita et al., 2009; Hasegawa et al., 2010). Furthermore,
S1P receptors are expressed in neurons, astrocytes, and microglial
cells. S1P acts on these cells directly and exerts effects that include
astrocyte proliferation and migration, oligodendrocyte differenti-
ation and cell survival, and neurite outgrowth and neurogenesis
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(Dev et al., 2008). Thus, S1P is considered to be an important
inﬂammatory mediator in the ischemic brain.
ROLE OF TLR
Leukocyte inﬁltration is an essential step in the progression of
post-ischemic inﬂammation. However, the mechanisms that acti-
vate these inﬁltrating immune cells, macrophages, and lympho-
cytes, are not yet fully clariﬁed. TLRs are an essential type of
receptor for innate and non-speciﬁc immune response to general
pathogens such as bacteria, viruses, and so on. The demonstration
that TLR2 and TLR4 are pivotal for sterile organ injury, including
ischemic brain injury, has recently attracted attention (Chen et al.,
2007; Tang et al., 2007).
Toll-like receptors are expressed on both leukocytes and brain
cells, although whether the effect of TLRs on brain cells is
neurotoxic or neuroprotective remains unclear. TLR stimulation
in macrophages and lymphocytes induces strong and various
inﬂammatory responses. In ischemic brain injury, post-ischemic
inﬂammation and subsequent ischemic damage depend on TLR2
and TLR4, but not TLR9 (Tang et al., 2007; Hyakkoku et al.,
2010). TLR2- or TLR4-deﬁcient mice demonstrate both signiﬁ-
cant reduction of infarct volume and suppression of neurotoxic
inﬂammatory responses. Analysis of bone marrow chimeric mice
indicates that TLRs in inﬁltrated immune cells, but not in residen-
tial microglia, have a neurotoxic effect on ischemic brain injury
(Yang et al., 2011). In addition, mice lacking MyD88, the adaptor
protein under almost all TLR signaling cascades other than TLR3,
are reported to show no improvement of ischemic brain injury
(Famakin et al., 2011). These results indicate that the function of
TLRs may be dependent on kind of cells in brain.
Toll-like receptor-2 or TLR4 deﬁciency suppresses inﬂamma-
tory cytokine expression in inﬁltrating immune cells on day
1 after brain ischemia (Shichita et al., 2012). Although both
TLR2 and TLR4 signaling cascades are essential triggers for post-
ischemic inﬂammation, and activators of inﬁltrating immune
cells, the particular molecules that activate TLR2 and TLR4 in
the ischemic brain remain unclear. Because the brain is a sterile
organ, pathogens derived from bacteria or viruses are completely
lacking in the normal and ischemic brain. This indicates that
certain endogenous molecules released from necrotic brain cells
become TLR stimulators, and several endogenous molecules have
indeed been reported to activate TLR signaling cascades. Such
endogenous molecules are called danger associated molecular pat-
terns (DAMPs), and are considered to be danger signals or alarm
molecules that warn immune cells of tissue and cellular injury.
DAMPs IN INJURED BRAIN
Several molecules in the brain have been reported as DAMPs.
Heat shock proteins (HSPs), β-amyloid (Aβ), hyaluronan, heparin
sulfate, DNA or RNA immune complex, oxidized low-density
lipoproteins (oxLDL),andothers, can stimulateTLRs (Marsh et al.,
2009; Rivest, 2009; Yanai et al., 2009; Stewart et al., 2010; Zhang
et al., 2010). However, it remains unclear which molecule is the
most important for triggering post-ischemic inﬂammation and
inﬂammatory cytokine expression.
High mobility group box 1 (HMGB1) is a well-elucidated
DAMP and is also implicated in ischemic brain injury (Kim et al.,
2006; Liu et al., 2007; Hayakawa et al., 2010). HMGB1 increases
vascular permeability and promotes BBB breakdown (Zhang et al.,
2011). HMGB1, which is localized in cell nuclei in the normal
brain, translocates into the cytosolic compartment and is released
into the extracellular compartment in the ischemic condition.
The administration of anti-HMGB1-neutralizing antibody pro-
tects the BBB and reduces infarct volume. Thus, HMGB1 is an
essential DAMP in ischemic brain injury. Extracellular release of
HMGB1 is observed within 6 h after stroke onset, but is dimin-
ished by 12 h after the onset (Qiu et al., 2008; Zhang et al., 2011).
Thereafter, the inﬁltration of immune cells and the production
of inﬂammatory cytokines become evident. This indicates that
HMGB1 may not directly activate inﬁltrating immune cells in the
ischemic brain.
We have identiﬁed the peroxiredoxin (Prx) family proteins as
strong inducers of inﬂammatory cytokines in inﬁltrating immune
cells (Shichita et al., 2012). Prx family proteins are known to
exert a protective effect by catalyzing ROS. In the ischemic brain,
the expression of Prx within brain cells is increased by ischemic
stress, and such intracellular Prx is thought to be neuroprotective
(Patenaude et al., 2005; Rashidian et al., 2009; Figure 2). How-
ever, as necrosis occurs, this Prx is released into the extracellular
compartment where they induce inﬂammatory cytokine expres-
sion in inﬁltrating immune cells by stimulating TLR2 and TLR4
(Figure 2). It is interesting to note that the Prx family proteins
have a common active region for TLR activation and are extracel-
lularly released over 12 h after stroke onset, which coincides with
the timing of leukocyte inﬁltration. Thus, Prx has two opposing
functions, one inside, and one outside, brain cells. Furthermore,
there is a time lag aswell as functional differences betweenHMGB1
and Prx (Figure 3).
T LYMPHOCYTES IN ISCHEMIC BRAIN INJURY
It has been recently suggested that T lymphocytes play a role as
mediators in the delayed phase of brain ischemia (Yilmaz et al.,
2006). The number of inﬁltrating T lymphocytes in ischemic brain
tissue increases over 24 h after stroke onset and reaches its peak
in the delayed phase (around day 3; Schroeter et al., 1994; Jan-
der et al., 1995). Inﬁltrating T lymphocytes appear to be localized
FIGURE 2 |Two opposing functions of Prx, one inside, and one outside,
brain cells. Ischemic stress increases Prx expression within brain cells,
which contributes to their survival by catabolizing reactive oxygen species
(ROS).When ischemic phenomena ﬁnally result in necrosis, the Prx
released from necrotic brain cells into the extracellular compartment then
functions as a strongTLR2 andTLR4 stimulator (DAMP) for the inﬁltrating
macrophages in ischemic brain tissue.
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FIGURE 3 | Post-ischemic inflammation triggered by DAMPs and
infiltrating immune cells. At the hyperacute phase of brain ischemia
(within 6 h after stroke onset), HMGB1 is released from brain cells and
induces BBB breakdown. Following this, blood cells begin to inﬁltrate into
ischemic brain tissue via disrupted vessels during the acute phase of
ischemia (12–24 h after stroke onset). Prx is extracellularly released from
necrotic brain cells and activates inﬁltrating macrophages via TLR2 and
TLR4. Activated macrophages produce inﬂammatory cytokines (IL-23, IL-1β,
TNF-α, etc.) which promote ischemic brain injury. At the delayed phase of
brain ischemia (more than 24 h after stroke onset), IL-23 induces IL-17
production from γδT lymphocytes, which further enhances ischemic
damage. Thus, HMGB1 is a hyperacute DAMP, while Prx is secondarily
active in post-ischemic inﬂammation, during the acute phase.
to the infarct boundary zones, typically close to blood vessels.
By Percoll gradient centrifugation, inﬁltrating immune cells have
been analyzed (Shichita et al., 2009). The number of inﬁltrating
immune cells reaches the peak at day 3 after stroke onset and most
of these are macrophages. Approximately 1∼ 1.5% of immune
cells are T lymphocytes which are consisted of 30∼ 40% CD4+
helper T lymphocytes, 20∼ 30% γδT lymphocytes, and 20∼ 30%
CD8+ cytotoxic T lymphocytes. Inﬂammatory cytokines, IL-1β,
TNF-α, IL-23, and IL-12 have been shown to be produced from
macrophage and play important roles in promoting brain injury.
However, role of various cytokines from T lymphocytes, such as
IFNγ and IL-17 in ischemic brain injury has not been clariﬁed.
Although the function of these inﬁltrating T lymphocytes in
the ischemic brain is not yet clear, T lymphocytes, on the whole,
are considered to act as a neurotoxic effector. This is indicated
by the fact that severe combined immunodeﬁcient (SCID) mice,
and recombination activating gene (RAG)-deﬁcient mice, both of
which lack T and B lymphocytes, reveal signiﬁcant reduction of
infarct volume (Yilmaz et al., 2006; Hurn et al., 2007). In addi-
tion, the depletion of CD4+ (helper) or CD8+ (cytotoxic) T
lymphocytes, but not one of the B lymphocytes, is reported to
attenuate ischemic brain damage. There is a report that regulatory
B lymphocytes protect brain from ischemic damages; however, the
neurotoxic effect of lymphocytes is considered to be majorly made
by T lymphocytes (Ren et al., 2011). It will be important to eluci-
date which subtype of lymphocytes is implicated in ischemic brain
injury (see T Lymphocyte Cytokines in Ischemic Brain Injury).
It is not yet clear whether a speciﬁc antigen in the brain is
involved in the activation of these inﬁltrating T lymphocytes.
Up to now, it has been thought likely that these T lymphocytes
mediate antigen-independent, innate inﬂammatory responses,
because post-ischemic inﬂammatory responses have been shown
to be driven by the innate immune system. However, some reports
suggest the importance of antigen recognition by T lymphocytes
in ischemic brain injury. Treatment with T cell receptor (TCR) lig-
ands, which are major histocompatibility complex (MHC) class II
molecules bound to myelin peptides, is protective against ischemic
brain injury (Subramanian et al., 2009). Infarct size inmyelin basic
protein (MBP) tolerized animals has been shown to be reduced
compared to that in control mice. Thus, there is a possibility that
some T lymphocyte subsets speciﬁcally tolerized to brain proteins
could be protective to ischemic brain injury (Becker et al., 2003;
Becker, 2009). This idea is supported by the recent ﬁnding that
regulatory T lymphocytes are protective to ischemic brain injury
(Liesz et al., 2009).
T LYMPHOCYTE CYTOKINES IN ISCHEMIC BRAIN INJURY
T lymphocytes are considered to mediate ischemic brain injury
by producing various cytokines, and IFN-γ and IL-4 are well-
known classical examples. In ischemic injury, IFN-γ is thought
to be neurotoxic, as it acts on neurons directly and induces
apoptotic neuronal cell death in vitro (Lambertsen et al., 2004).
However, a protective effect by the IFN-γ deﬁciency has not been
observed, and the role of IFN-γ in ischemic brain injury is con-
troversial (Lambertsen et al., 2004; Yilmaz et al., 2006). IL-12
is produced from myeloid cells such as macrophages, dendritic
cells, neutrophils, and so on, and is important for the differenti-
ation of IFN-γ-producing helper T lymphocytes (Th1). IL-12 is
expressed in ischemic brain tissue by inﬁltrating immune cells, but
its function has not been fully elucidated.
IL-4 may have the potential to attenuate ischemic damage and
promote tissue repair, since IL-4-deﬁcient mice demonstrate exac-
erbated ischemic damage and neurological deﬁcit (Xiong et al.,
2011). Although the emerging recognition of the function of IL-4
for tissue repair has recently attracted attention, whether or not
IL-4 is directly implicated in tissue repair in ischemic brain injury
is still unclear (Chen et al., 2012).
IL-10 is an immunosuppressive cytokine and is thought to
have a neuroprotective effect in ischemic brain injury. IL-10 is
produced from regulatory T lymphocytes (Treg) and suppresses
the neurotoxic function of TNF-α and IFN-γ (Liesz et al., 2009).
The overexpression of IL-10 by an adenovirus vector protects hip-
pocampal neurons against apoptotic cell death (Ooboshi et al.,
2006).
IL-17 is an emerging therapeutic target for various organ
injuries. IL-23 has been reported to be essential for IL-17 induc-
tion from T lymphocytes, and to play a critical role in EAE
(Cua et al., 2003). In ischemic brain injury, IL-23 is produced
by inﬁltrating macrophages on day 1, and it induces IL-17 pro-
duction from γδT lymphocytes in the delayed phase (Figure 3).
Both IL-23 KO mice and IL-17 KO mice show signiﬁcantly atten-
uated ischemic brain damage on day 4. The IL-17 receptor is
ubiquitously expressed in brain cells and modiﬁes various inﬂam-
matory responses in the central nervous system. IL-17 has been
reported to promote the expression of inﬂammatory cytokines
and chemokines from macrophages (Fossiez et al., 1996). IL-17
alsomodulates the epithelial barrier function by promotingMMPs
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and ICAM-1 expression (Kebir et al., 2007; Ifergan et al., 2008).
Although it remains unknown whether IL-17 directly affects
neurons, IL-17 is thought to be a promising therapeutic tar-
get for suppressing post-ischemic inﬂammation. Thus, IL-23-
induced IL-17-producing γδT lymphocytes play a pivotal role
in the delayed phase of brain ischemia (Figure 4). IL-17 pro-
duction from γδT lymphocytes requires only IL-1β and IL-23
stimulation, but not speciﬁc TCR stimulation, and IL-6 and TGFβ
stimulation are indispensable for IL-17-producing helper T lym-
phocyte (Th17) differentiation (Sutton et al., 2009). Thus, it is
reasonable that γδT lymphocytes mediate ischemic brain injury,
given that γδT lymphocytes produce IL-17 more rapidly than
does Th17.
THE POSSIBILITY OF MEDICAL INTERVENTION IN
POST-ISCHEMIC INFLAMMATION
Post-ischemic inﬂammation in the brain is considered to have two
opposing functions in stroke patients; one beneﬁcial, the other
harmful. Post-ischemic inﬂammation promotes brain swelling
(brain edema) which leads to the compression of normal brain
tissue surrounding the ischemic core and the exacerbation of neu-
rological deﬁcits. This undesirable effect of post-ischemic brain
inﬂammation should be suppressed by medical intervention when
possible. However, post-ischemic inﬂammation is also thought to
promote tissue repair in the recovery phase of ischemic stroke.
Thus, suppression of all inﬂammatory responses in ischemic
brain tissue is not always effective, due to their involvement
in both ischemic injury and tissue repair processes. To create
novel neuroprotective strategy, it may be possible to control
the balance between the neurotoxic and neuroprotective effects
of post-ischemic inﬂammation by targeting speciﬁc inﬂamma-
tory mediators. For example, therapy which both suppresses the
FIGURE 4 | Schematic model of IL-23/IL-17 inflammatory pathway in
ischemic brain tissue. Inﬁltrating macrophages produce IL-23 and IL-12,
which induce IL-17-producing γδT lymphocytes and IFN-γ-producing helper T
lymphocytes (Th1), respectively. IL-17 from γδT lymphocytes acts on
macrophages and brain cells directly, and promotes the expression of
inﬂammatory mediators that enhance apoptotic neuronal cell death and
BBB breakdown.
inﬂammatory subset of T lymphocytes (e.g., IL-17-producing γδT
lymphocytes) and promotes Treg function may be desirable.
It is possible that administration of γδTCR-depleting anti-
body or anti-IL-12/IL-23p40 antibody [p40 is a common sub-
unit of the IL-12 heterodimer (p35/p40) and IL-23 heterodimer
(p19/p40)]will become a therapeutic tool for ischemic stroke (Shi-
chita et al., 2009; Konoeda et al., 2010). Thus, neuroprotective
therapies for ischemic brain injury may be developed by targeting
the IL-23/IL-17 inﬂammatory pathway. Furthermore, one of the
most advantageous points of therapy targeting IL-17-producing
T lymphocytes is its long therapeutic time window. Since current
globally approved therapy is limited to intravenous administration
of tPA, which should be performed within 4.5 h after stroke onset,
further elucidation of the inﬂammatorymechanisms of the T lym-
phocytes that inﬁltrate the ischemic brain during the 24-h-period
after stroke onset is needed.
FTY720 is one of the most promising therapeutic tools for
ischemic stroke at this time (Wei et al., 2011). FTY720 decreases
the number of inﬁltrating T lymphocytes, including γδT lympho-
cytes. The most troublesome side effect of FTY720 administration
is the increased incidence of bacterial pneumonia after stroke
(Meisel and Meisel, 2011). It is possible that FTY720 interferes
with peripheral lymphocyte distribution in the body after stroke
and thus inhibits the protective function of peripheral T lympho-
cytes against bacterial infection.Although it has been reported that
FTY720 does not promote spontaneous bacterial infection after
experimental stroke in mice, future studies aimed at developing
effective clinical interventions for stroke patients should seek to
minimize this kind of detrimental effect of FTY720 (Pfeilschifter
et al., 2011).
In conclusion, research has gradually shed light on the mech-
anisms of post-ischemic inﬂammation. A deeper understanding
of these intricacies in the context of medical intervention should
enable the development of novel neuroprotective strategies that
are more effective and have a longer therapeutic time window
(Figure 5).
FIGURE 5 | Strategy for developing neuroprotective therapy by
suppressing neurotoxic inflammatory response.The targeting of speciﬁc
inﬂammatory mediators from macrophages andT lymphocytes can
attenuate neurotoxic inﬂammatory reactions.
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